Market News & Trends
Artelo Biosciences Announces New Data From Initial Food Effect Investigation With a Novel Non-Opioid Treatment Candidate for Persistent Pain
Artelo Biosciences, Inc. recently announced encouraging results from its preliminary food effect evaluation with ART26.12. This assessment was conducted as a part of the successful single…
Immuneering Announces Clinical Supply Agreement With Lilly to Evaluate Atebimetinib in Combination With Olomorasib
Immuneering Corporation recently announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports…
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
HCW Biologics Inc. recently announced its scientists have successfully developed second-generation, pembrolizumab-based immunotherapeutics against solid tumors, particularly for pancreatic and ovarian cancer, using its novel…
Biofrontera Announces Last-Patient-Out in Phase 2b Study of Ameluz Topical Gel for the Treatment of Moderate-to-Severe Acne Vulgaris
Biofrontera Inc. recently announced the final patient in its Phase 2b clinical trial evaluating Ameluz (aminolevulinic acid hydrochloride) for the treatment of moderate-to-severe acne vulgaris…
Larkspur Biosciences Announces Discovery of a First-in-Class Degrader of the Lipid Kinase PIP4K2C for the Treatment of Microsatellite Stable Colorectal Cancer
Larkspur Biosciences recently announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer…
Advanz Pharma & Alvotech Receive European Approval for Mynzepli, Biosimilar to Eylea
Alvotech and Advanz Pharma Holdco Limited recently announced the European Commission has approved Mynzepli as a biosimilar to Eyle (aflibercept), in a pre-filled syringe and…
Cube Biotech & X-Chem Partner to Enable DNA-Encoded Library Screening of NativeMP-Stabilized Membrane Proteins
Cube Biotech and X-Chem recently announce the successful conclusion of Project DEL-MP, a collaborative initiative demonstrating that copolymer-stabilized membrane proteins are not only suitable for DEL…
Medicus Pharma Provides Update on D-MNA Clinical Development Program for the Treatment of Basal Cell Carcinoma
Medicus Pharma Ltd. recently announced, following the acceptance of the Type C meeting request by the USFDA, it has submitted its queries in writing and…
BioAegis Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness
BioAegis Therapeutics recently announced the US FDA has granted Fast Track designation to its lead product candidate, recombinant human plasma gelsolin (rhu-pGSN), for the treatment…
Thermo Fisher Scientific Launches Gibco Expi293 PRO Expression System to Accelerate Protein Research & Therapeutic Drug Development
Thermo Fisher Scientific has introduced the Gibco Expi293 PRO Expression System, a next-generation HEK293 transient expression system designed to deliver exceptional protein yields for a…
Iterum Therapeutics Launches the First & Only Oral Penem Antibiotic in the US
Iterum Therapeutics plc recently announced the US commercial launch of ORLYNVAH (sulopenem etzadroxil and probenecid) oral tablets. The US FDA approved ORLYNVAH for adult women…
Mural Oncology Announces Agreement to be Acquired by XRA 5 Corp.
Mural Oncology plc and XOMA Royalty Corporation recently announced they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed…
Trethera Awarded $3-Million NIH Grant to Advance First-In-Class Drug for the Treatment of Lupus
Trethera Corporation recently announced it has been awarded a $3-million Small Business Innovation Research (SBIR) grant from the National Institute of Health (NIH). The award…
BioMed X & Novo Nordisk Launch New Collaboration in Oral Peptide Drug Delivery
BioMed X recently announced the launch of a new collaboration with Novo Nordisk, a leading global healthcare company headquartered in Denmark. This partnership aims to…
Memo Therapeutics Publishes Phase 1 Study for Neutralizing Antibody Targeting BKPyV Infection in Clinical & Translational Science
Memo Therapeutics AG has published Phase 1 clinical data in Clinical and Translational Science, highlighting the safety, tolerability, and pharmacokinetics (PK) of its lead clinical…
Rein Therapeutics Wins Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics recently announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the company to initiate its Phase 2 RENEW clinical trial…
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
ALX Oncology Holdings Inc. recently announced the first patient has been dosed in the company’s Phase 1 clinical trial for ALX2004, a potential best- and…
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
BiomX Inc. recently announced the US FDA has placed a clinical hold on the Phase 2b trial of BX004 for the treatment of patients with…
Invivyd Announces Continued Neutralizing Activity of PEMGARDA & VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG
Invivyd, Inc. recently announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA (pemivibart) against the currently dominant and growing XFG variant of SARS-CoV-2.…
Upperton Pharma Solutions Awarded VaxHub Sustainable Grant to Advance Oral Vaccine Delivery in Partnership With the University of Oxford’s Pandemic Sciences Institute
Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), has been awarded a grant as part of the first VaxHub Sustainable Platform…
